amantadine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Babu, E; Ganapathy, V; Ho, HT; Itagaki, S; Wang, J; Zhou, M | 1 |
| Altagracia, M; Kravsov, J; Rios, C; Rojas, P | 1 |
| Chan, WW; Rausch, WD; Riederer, P; Schallauer, E; Weiser, M | 1 |
| Lieberman, AN | 1 |
| Altagracia, M; Kravzov, J; Rios, C; Rojas, P | 1 |
| Blanchet, PJ; Chase, TN; Konitsiotis, S | 1 |
| Archer, T; Danysz, W; Fredriksson, A; Quack, G | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Pires, D; Visanji, NP; Voon, V | 1 |
| Antipova, TA; Kovalev, GI; Logvinov, IO; Zimin, IA | 1 |
| Han, HS; Kim, IS; Lee, BH; Lee, MJ; Wang, K | 1 |
| Aron Badin, R; Auguet, M; Bertrand, A; Boulet, S; Brouillet, E; Chabrier, PE; Dollé, F; Gaillard, MC; Guillermier, M; Hantraye, P; Jan, C; Malgorn, C; Savasta, M; Spinnewyn, B; Van Camp, N | 1 |
| Ivanova, EA; Kapitsa, IG; Nepoklonov, AV; Val'dman, EA; Voronina, TA | 1 |
| Bourque, M; Di Paolo, T; Dickens, D; Grégoire, L; Patel, W; Snodgrass, R | 1 |
13 other study(ies) available for amantadine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.
Topics: Animals; Cell Membrane; Electrophysiological Phenomena; Equilibrative Nucleoside Transport Proteins; Female; Humans; Membrane Potentials; Organic Cation Transport Proteins; Xenopus laevis; Xenopus Proteins | 2012 |
Partially protective effect of amantadine in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Corpus Striatum; Dopamine; Homovanillic Acid; Male; Mice; Parkinson Disease, Secondary | 1992 |
Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amantadine; Animals; Caudate Nucleus; Corpus Striatum; Dopamine; Drug Interactions; Female; Gerbillinae; Homovanillic Acid; Hydroxyindoleacetic Acid; Male; Parkinson Disease, Secondary; Selegiline; Serotonin | 1990 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Rats | 1986 |
Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Brain Chemistry; Corpus Striatum; Dopamine; Dopamine Agents; Homovanillic Acid; Hydroxyindoleacetic Acid; Male; Mice; Parkinson Disease, Secondary; Probenecid; Serotonin | 1993 |
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Injections, Subcutaneous; Levodopa; Macaca fascicularis; Neurologic Examination; Parkinson Disease, Secondary; Receptors, N-Methyl-D-Aspartate | 1998 |
Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Levodopa; Male; Memantine; Mice; Mice, Inbred C57BL; Motor Activity; Parkinsonian Disorders; Recovery of Function | 2001 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Grooming; Hallucinations; Levodopa; Parkinsonian Disorders; Psychomotor Agitation; Psychotic Disorders; Statistics, Nonparametric; Stereotyped Behavior | 2006 |
[A comparative study of hemantane and amantadine effects on dopamine transporter expression in brain of normal and MPTP-treated C57BL/6 mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Amantadine; Animals; Antiparkinson Agents; Brain; Dopamine Plasma Membrane Transport Proteins; Drug Synergism; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders | 2011 |
Molecular imaging of cell death in an experimental model of Parkinson's disease with a novel apoptosis-targeting peptide.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Apoptosis; Brain; Cell Count; Disease Models, Animal; Fluorescein-5-isothiocyanate; In Situ Nick-End Labeling; Injections; Male; Mice; Mice, Inbred C57BL; Molecular Imaging; Neurons; Parkinson Disease; Peptides; Protein Transport; Tyrosine 3-Monooxygenase | 2012 |
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antioxidants; Antiparkinson Agents; Behavior, Animal; Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Disease Models, Animal; Dopamine Agents; Dyskinesias; Immunohistochemistry; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Neurons; Oxidative Stress; Parkinson Disease; Positron-Emission Tomography; Thiazoles | 2013 |
[Study of hemantane effects in rats on a model of early (premotor) stage of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Amantadine; Animals; Antiparkinson Agents; Cognition; Drug Administration Schedule; Male; Neurotoxins; Parkinson Disease, Secondary; Rats; Time Factors | 2012 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Glycine; Levodopa; Macaca fascicularis; Neuroprotective Agents; Parkinsonian Disorders; Pilot Projects; Prodrugs; Receptors, N-Methyl-D-Aspartate | 2022 |